Promising Penny Stocks To Watch In September 2026

The United States market has shown positive momentum, rising 2.5% over the last week and 14% over the past year, with earnings expected to grow significantly in the coming years. While penny stocks may seem like a relic from earlier market days, they continue to offer intriguing opportunities for investors seeking growth at lower price points. By focusing on smaller or newer companies with strong balance sheets and solid fundamentals, investors can uncover potential gems that might provide both stability and upside potential.

Let's take a closer look at a couple of our picks from the screened companies.

SIGA Technologies (SIGA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SIGA Technologies, Inc. is a commercial-stage pharmaceutical company that specializes in the health security market in the United States, with a market cap of $227.05 million.

Operations: The company generates its revenue primarily from its Pharmaceuticals segment, totaling $53.66 million.

Market Cap: $227.05M

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, has experienced a decline in revenue and net income for the second quarter of 2026 compared to the previous year. Despite being unprofitable with negative return on equity, SIGA's short-term assets significantly exceed its liabilities, providing financial stability. The company is debt-free and trades at a substantial discount to its estimated fair value. Recent index adjustments saw SIGA removed from several growth benchmarks but added to defensive indices. A shelf registration filing indicates potential capital raising efforts through common stock offerings valued at US$28.08 million.

• Navigate through the intricacies of SIGA Technologies with our comprehensive balance sheet health report here.
• Examine SIGA Technologies' earnings growth report to understand how analysts expect it to perform.

OPKO Health (OPK)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: OPKO Health, Inc. is a healthcare company operating in the United States, Ireland, Chile, Spain, Israel, Mexico and internationally with a market cap of approximately $1.26 billion.

Operations: The company's revenue is primarily derived from its Diagnostics segment, which generated $313.07 million, and its Pharmaceutical segment, contributing $274.83 million.

Market Cap: $1.26B

OPKO Health, Inc. has faced challenges with profitability, reporting a net loss for the second quarter of 2026 despite revenue growth to US$163.58 million from the previous year. The company recently expanded its financing relationship with HealthCare Royalty by issuing US$125 million in senior secured notes, backed by royalty interests in mazdutide sales in China. This move provides non-dilutive capital while maintaining long-term royalty participation. OPKO's seasoned management and board offer stability; however, earnings are forecasted to decline over the next three years, and share price volatility remains high compared to peers.

• Dive into the specifics of OPKO Health here with our thorough balance sheet health report.
• Explore OPKO Health's analyst forecasts in our growth report.

UP Fintech Holding (TIGR)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: UP Fintech Holding Limited offers online brokerage services primarily for Chinese investors across various regions including New Zealand, the Cayman Islands, Singapore, and the United States, with a market cap of approximately $870.45 million.

Operations: The company generates revenue primarily from its brokerage services, totaling approximately $607.24 million.

Market Cap: $870.45M

UP Fintech Holding Limited, with a market cap of US$870.45 million, recently reported Q2 2026 earnings with revenue rising to US$182.27 million from US$138.72 million the previous year, though net income slightly declined to US$39.36 million. The company has reduced its debt significantly over five years and maintains more cash than total debt, indicating strong financial health. Despite lower profit margins compared to last year and negative earnings growth over the past year, UP Fintech is trading at a good value relative to its peers and industry while maintaining high-quality earnings without significant shareholder dilution recently.

• Click to explore a detailed breakdown of our findings in UP Fintech Holding's financial health report.
• Gain insights into UP Fintech Holding's future direction by reviewing our growth report.

Key Takeaways

• Get an in-depth perspective on all 319 US Penny Stocks by using our screener here.
• Curious About Other Options? AI is about to change healthcare. These 132 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com